Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3
about
Hepatocellular carcinoma: Review of disease and tumor biomarkersBiomarkers for the early diagnosis of hepatocellular carcinomaDiagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-AnalysisBiomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and chinaDiagnosis of hepatocellular carcinoma.Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach.Early detection of hepatocellular carcinoma through surveillance using biomarkersCurrent management of hepatocellular carcinoma.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma.Updates in the management of hepatocellular carcinomaEvaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis.Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation.Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients.Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular CarcinomaPerformance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population.Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again.Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China.Surveillance and Diagnosis of Hepatocellular Carcinoma.A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors.A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma.Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy.Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring.Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics.Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in ChinaFactors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.miRNA for diagnosis and clinical implications of human hepatocellular carcinoma.Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma.Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives.Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis.Ongoing challenges in the diagnosis of hepatocellular carcinoma.Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?Detection of MicroRNA in Hepatic Cirrhosis and Hepatocellular Carcinoma in Hepatitis C Genotype-4 in Egyptian Patients.Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma.
P2860
Q26750796-3F16FD86-EB85-48C3-A5F0-F845E79494E7Q26784418-C339EB0A-4D53-4A58-92DC-34A86DF41D7CQ26863560-BE878407-C0AA-4A09-A491-CC29D48B4641Q27003291-F2C1878D-00FC-48D3-8A1B-3BE6596C99C0Q30490554-504A2075-7085-4931-A7B4-DD63004AFF1AQ33429064-5FC248C3-18C8-4B38-8207-E17BDA232EA6Q33571506-A5044F7E-2D68-4914-94F0-859DDECD4104Q33582165-74E261A1-FB3D-4E18-B313-6DF62554C52CQ33643368-536DF6CF-BE97-459F-9E01-40945A901BC0Q33718951-E543E784-DE19-4057-85F9-37AA88149963Q34485283-68FA3D25-BE27-4601-9FE0-F66AD9348620Q34571160-D3EF7FF2-BBB0-4AF6-82D5-57C4154E9F5EQ35062428-F63897A9-EE69-4B27-A9DA-C55B072F84CBQ35677834-FE8BEB0A-5FD2-4F22-8E38-C41EDB355EEAQ35850889-1DB88EB4-9C17-47D5-9F01-FFEE2BBD4DE8Q35960878-243B2D7F-1D3D-4489-893A-7CF4F419C631Q35964785-CE1DAB0C-CC61-464E-B307-7853971C7438Q36082480-F5D2CFFE-DF0E-4356-AEA3-D14175086AE4Q36150993-99BF8903-16A0-4D18-8471-2AB75A1A4349Q36812480-477E3751-38FF-4266-846A-98B61558E58FQ37031700-FCA6AC37-F1C6-4B26-BA0D-6924E8F8D350Q37206392-636B0F31-3950-4B4C-A7E3-4B38A92BD7BAQ37330554-79AF896C-D4C3-4664-AE9B-BD4017347C58Q37351966-10187BCE-D8AB-4F9E-A8A5-FF0F183D7121Q37520019-D80A77CC-6EDB-423E-A252-A7F45CB403D0Q37534945-A0DA3AEF-AD78-4571-BC36-FB21BD9DB7F0Q37578500-24DF7D42-0645-4D87-88D5-DFA48EEE722BQ37584690-BB16D2E3-1C02-4ABE-9462-7AFC7BF5CA76Q37684651-590B6DE6-2111-43D1-AE19-451BEAFA640FQ38568853-CA2A8789-518D-4484-BCD5-2C143E8352EFQ38588428-0A03FCA2-FF08-4141-92B4-B8222F278404Q38589516-B11C611B-769A-45D5-A462-203DD8BA7E7DQ38637305-3C452A79-9A46-4F9F-A520-C0EB3ACDE349Q38646886-AF5ABEB6-B800-4CA5-B645-98D188A5C6ABQ39197775-45DB8EF9-6F41-4FC8-8C49-473C3AF91959Q40161142-F948EE67-73B7-47AF-8ADF-857DD166A6B9Q40300595-5AC7FB19-CB0E-4CCD-A45F-85B4D98DBDC9Q40373005-88EF6FCF-C46A-4773-8D05-58012F908B5AQ40707167-81C0DA9A-2E78-41FE-A2CB-A1BE35A16F9CQ40836505-711A2E01-A661-493F-A826-435AA17366E3
P2860
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@ast
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@en
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@nl
type
label
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@ast
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@en
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@nl
prefLabel
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@ast
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@en
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@nl
P2093
P3181
P356
P1433
P1476
Risk factors for hepatocellula ...... arison of AFP, DCP, and AFP-L3
@en
P2093
Anna S Lok
Grace L Su
Jorge A Marrero
Jose C Hernandez
Michael L Volk
P3181
P356
10.3233/CBM-2007-3202
P407
P577
2007-01-01T00:00:00Z